Zai Lab
Rui Mu is an experienced finance and business development professional currently serving as Associate Director of Business Development at Zai Lab since May 2022. Prior roles include Senior Finance Manager for FP&A in R&D at Amgen, Finance Manager at Amgen, and Global Finance and Operation Manager at Jehmi, where Rui built a global finance team and managed cryptocurrency asset flow. Previous experience includes managerial positions at Wilshire Associates, East West Bank, and Morgan Stanley, focusing on cash management, fund operations, and financial analysis. Rui holds an MBA in Finance and Financial Management Services from USC Marshall School of Business, as well as Master's and Bachelor's degrees in Economics and Business Management from Dongbei University of Finance and Economics.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.